Soares Débora Vieira, Conceição Flávia Lúcia, Vaisman Mário
Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brazil.
Arq Bras Endocrinol Metabol. 2008 Jul;52(5):872-8. doi: 10.1590/s0004-27302008000500020.
Sheehan's syndrome is characterized by hypopituitarism that occurs as a result of ischemic pituitary necrosis due to severe postpartum hemorrhage. Nowadays it is not usually seen in developed countries because of the improvements in obstetric care. However, in developing countries it is still frequent and probably one of the most common causes of hypopituitarism. Most patients usually present it months to years later, with a history of failure of postpartum lactation, failure to resume menses and other signs of panhypopituitarism. In mild forms of the disease, patients may remain undetected and do not receive treatment for many years. Early diagnosis and appropriate treatment are important to reduce the morbimortality of the patients with Sheehan's syndrome. The aim of this review is to describe clinical, laboratory and therapeutic aspects of Sheehan's syndrome, including our experience in the replacement of recombinant GH in these patients.
席汉综合征的特征是由于严重产后出血导致垂体缺血性坏死而发生垂体功能减退。如今，由于产科护理的改善，在发达国家通常已不见此病。然而，在发展中国家它仍然很常见，可能是垂体功能减退最常见的原因之一。大多数患者通常在数月至数年后出现，有产后无乳、月经未复潮及其他全垂体功能减退的体征。在疾病的轻度形式中，患者可能多年未被发现且未接受治疗。早期诊断和适当治疗对于降低席汉综合征患者的病残率和死亡率很重要。本综述的目的是描述席汉综合征的临床、实验室和治疗方面，包括我们在这些患者中使用重组生长激素替代治疗的经验。
